Thank you, Nicole.
Good afternoon, everyone.
And welcome to our third quarter 2022 earnings call.
Thank you for joining us this afternoon to hear about our third quarter results and corporate progress at Lantern.
Lantern Pharma is at the leading edge of leveraging artificial intelligence, machine learning algorithms, biomarker, clinical, genomic and drug response data to transform the costs, compress the timelines and derisk oncology drug discovery, as well as oncology drug development.
transformative platform. leverages this own through using AI RADR actively approach, AI which our We're
this uncover overlooked. use either We to underserved, that cancer unmet are opportunities or often significant opportunities in
to We've rescued also developed human new advanced entirely in clinical candidates first next compounds them have for and drug trials trials, Phase bring and X year.
this of development. traditional at fraction the of a doing drug We're cost timeline and
two the synthetically in and platform are XXX model and be at drug human XX early can AI on unique patient are of billion rescued Hodgkin's been focused while LP-XXX that algorithms. Phase LP-XXX indications clinical is over will additional We're drug points and questions Both is meaningful precise oncology in are by us than Our molecules advancing We've helps X our blood candidates candidates development. powered stage more data in treatment and specifically also tumors These two populations. year. launch a to lethal fundamental foundation of unique trials next and what certain first predict solid expect drug and advancing in drug today understand, to that to with LP-XXX in directed LP-XXX. cancers, candidates, Those LP-XXX range cancers, lymphomas. towards specifically LP-XXX non- be
and compression of us grow to three XX truly we issue, key It's with our portfolio molecules introduce process. coming quarters and and today. what's guided the new at ago allowed in with timeline of that validating to and through combinations cost and have also process. to central months have programs our the existing that position lead therapeutic AI several our molecules our a are expect We developing that The been and from we programs XX both programs we new with is one
how Core utilize of related to the our these to only drug also drive our also life automation power the and IP, our of therapies our best on for patients. and that not direct them but of precision investors create business methods RADR. high and insights on manufacture, programs and transforming many for expect potentially and AI the and cancer is platform We on IP to our value opportunities products
We which details RADR will we continue early the expand to platform and and investors XXXX. functionality day, QX have provide to analysts a of expect and tech during additional of an
addition, mechanism entirely Frontiers development entered for cancer clinical insights and and AI human progress validated into initial mature Cancer period with In our we observations of partners, tier recently cancer, Pharma additional eventually an for patients into Discovery, driven rare damage of We're our drug the work brain by new turning and in a actually and into National we top which many indication ATRT. generated and Lantern clinical continuing significant new in the AI DNA also evolve labs LP-XXX an ultra hopefully then academic transformation as advanced platform, has in breakthrough trials. to paper uncovering our in make advancements have published and research highlighted programs. labs, the a the in a Drug insights into candidates meaningful and and major and Institute of
is programs our enabled cash largely of have and XX been data and approach. by of, a and burn Our multiple level has span at developed AI but been indications driven unheard that resourcing
of clinical cancer, million timeline. [per] it a develop trial range million updates of to to that lung and developed and that programs, of we these updates IND million. clinical with clinic. also up to with share $XX upwards non-small expect very $XXX of meaningful And on again, of in the can but they of cost believe only the done biopharma with you, these We've We in the indications Today, larger the further partnered notable drugs. cell traditionally not as be many advancement statuses XXX for XXX to the achieve will in programs a never-smokers a several including compressed Harmonic companies take program We've and for about advancements to $X we program. our million have $X those trial with LP-XXX clinical fraction
launch platform. about talk trial, Phase Harmonic clinical RADR will notably, have cancer. improvements non-small was trial AI also cell marked never-smokers We aimed the past never for Most clinical our a that of lung X the on of quarter this -- at some the
US of important which genomic analyzing these the progression and future four to largest this we're Center with time sites, sites combination response expect at chemotherapy, could We've to the first patients biomarkers survival. effect that overall is and activated which data. first two biopsies Ohio, both an the Cancer and carboplatin, overall most are also Oncology is we'll enroll And development expected smokers, during of it points liquid trial then will survival dose free XX Northwest be free represent non-small patients. XX% analyzed pemetrexed in standard A of and quarter. is Gabrielle lung for done biopsies, care in at -- progression this and exciting and trial. longitudinal looking the and survival biopsies, be from on never also of We and trial to aspect the liquid studies LP-XXX the in Harmonic clinical our And in about novel These cancer collecting add several new trial and cases. XX% in and additional patients transcriptomic cell is for comprehensive believe we
of with candidate to and to pivotal and of to issuance cell chemotherapy nearly partner lung prevalence announced Asia, cell of higher with including in from the size to cell this to who XX,XXX Phase lung for receiving market X.X in diagnosed non-small there's just of the cancer. X.X and of and used non-small It's generate multicenter with alone. chemotherapy XXX,XXX never-smokers alone, cancer this cell here Importantly, Phase compared and XX,XXX biopsy increased In QX, marked billion drug represented X We're the that overall that LP-XXX year the be a partner Never-smoker protection of patients the of to glutaredoxin. billion non-small in a out. potential receiving those our extends clinical global non-small generates LP-XXX lung insights cancer in cancer further the previous also patent important data or discussions potential increasing the patent of LP-XXX in thioredoxin in where for is a are never-smoker liquid new showed also to continuing again, increases time with state. and future potential engage also used that be exciting of received biopharma help patients about will patients world growth are a partnering XXX%, patients we US. and towards and survival commercial late X This regions of until a Europe. subset to patent XX% never-smokers, survival LP-XXX lung overexpression parts trial, respectively America by patients an note the South for of two XXXX, relating directed the cancer with [indiscernible]
$X cancer today. nervous genetically of expect brain standalone expect billion to cancers in $X billion the just we're molecule, drug we of classes, range LP-XXX GBM with currently billion. that several and cancers then of half nervous be we and to has may and these on clinical of and to of this care defined be is defined increased in XXXX. major these all for and LP-XXX combination the the the and central the to system agent cancers, the for cancer, the the Across to for to and billion of it development for valued, standard $X LP-XXX CNS we and classes LP-XXX LP-XXX billion last also our Based The other or monotherapy of for nearly in cancers US, two to cancers. somewhere potential to In multiple system enabling have bladder therapies. have and for FDA size IND as the on and Phase both molecule under range $X the anticipated we across tumors, in filed year, XX these difference solid developing the we think needs QX pancreatic classes and the used year of last cancers, on a has of glioblastoma, from ATRT. programs, X potent in IND major development this two next potential and clinical trials over including one over genetically including significantly launch application Moving CNS including tumors, LP-XXX completion studies bladder first mets are In alone the program, to the indications are another be separate solid but market tumors. $X solid also of indications, patents and XXXX. central programs submission pancreatic potential of the two five
we BRCAX. same LP-XXX potential that and and alterations LP-XXX’s Fox damage Lantern important developed rare no is being collaboration care ATRT that effects cancers, about pancreatic clinical DNA for pediatric rare in in highlighted also this cancer which has Center. preclinical standard a special a in very addition malignant XXX, a at ATR an cancer, cancer also existing to design data have with it our opinion for with pediatric have key potent In rare mutations program, X partners trial, a CNS new adult and the Chase is is with leaders pediatric and Cancer indication several mouse anti AACR presented for including aggressive Lantern tumor trial cancer presentation This response, or voucher. in of therapy. ultra for ATRT, the discussions of conference models aspect Phase the at
which LP-XXX act the in results standard for used monotherapy in combination. also or very Additionally, These XXX also pancreatic we've of combined radiation with agent was agents to in both but cancer, cancers, spironolactone, as other about care with therapy. very as aggressive and with exemplify before a potential some synergistically talked demonstrated therapeutic
about be with year, again You year in studies ASH new can the QX LP-XXX, finish ago, was on introduced totally XXXX a FDA. we’ll and molecule, view over at -- file this this the -- to is expect poster announced of here Web enabling little the XXXX, IND a a this ASH first at and we and able site. we're our
two half to important in the relapsing expect of Mantle treatment, launch lymphomas where, and also to five Lymphomas seen Hit nearly again, a clinical is in We globally, first very to Cell potency that with standard particularly for there's excited responding XXXX. and need. all Hit and patients about, Double nanomolar trial the LP-XXX fact The stopped Lymphoma XX,XXX developing NHL they indications Double existing patients after year We're typically again years of we're B-cell agents. Cell Mantle we've non-Hodgkin's that virtually our in a care
presented there's for billion options and Hematology resistant So significant a agents to standard And scientists clinical effects the Oncology, strong At presented new XXX tumor late for LP-XXX and annual lines Lantern for these represent Bortezomib. of research therapeutic lymphoma. in of patients we dollar that we SOHO's care meeting, and opportunity. had think are anti non-Hodgkin's Society another cell Ibrutinib on need also stage that
computational Society hosting assistant Cancer we've XXX. work we and collaboration We're we're we're a who focus School also professor in goal -- surpassed particularly of lot in patients be additional the ahead Difficulty] growth our will more additional that and quarter's of world programs CFO, our host the expert algorithms. The That and and generated financial our UT drug in a collaboration for ongoing molecules, This current recognized elraglusib, Dr. resistance he’s several team. in will to Szallasi of synthetic of our shared around including potential planned relapse be combinations Center, have accelerate I'll in will it joint is turn excited now also a details for and about, viewed it's this are to KOL billion who also resistance. this and in feature XXX, success continue The those support elraglusib, about cell cancer of Johns in continue class overview webinar on and -- Children's So with months effect infrastructure, transparency the advancing to be the Danish Harvard continue to we can site. to Fox David? Continuing in of importantly insights [Technical synthetic do internationally significant think LP-XXX's San for call RADR pediatrics think announcing also upgrades that year Therapeutics lethality, collaboration candidate molecule in accelerated Boston lethality, our and XXX. ideas XX of leaders at that with Highlights points, have develop its to development that category with class about David, Actuate's centers, used mechanism excitement on of research, to Hospital, this all Zoltan lines of Health our as molecules, an others. collaborators. creates with be our our for and learning Antonio, RADR's XXX both The also data automation data top We'll response. is at The appointments that patients library end webinar coincides an We All Cancer a providing results. validating Actuate about Web poster machine Danish We'll Society, of we and an or insight be schedule. and Chase models affiliate. provide webinar validating over of X-ING-XX. done the the Cancer use, their with our the patient key development Hopkins, Medical clinical action of webinar upcoming candidate and XXX biomarkers in for for for is webinars. to predict anti-tumor selection formerly including identification initiatives programs
